273 related articles for article (PubMed ID: 37150829)
1. Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression.
Ning B; Tilston-Lunel AM; Simonetti J; Hicks-Berthet J; Matschulat A; Pfefferkorn R; Spira A; Edwards M; Mazzilli S; Lenburg ME; Beane JE; Varelas X
J Exp Clin Cancer Res; 2023 May; 42(1):116. PubMed ID: 37150829
[TBL] [Abstract][Full Text] [Related]
2. Aberrant epithelial polarity cues drive the development of precancerous airway lesions.
Tilston-Lunel A; Mazzilli S; Kingston NM; Szymaniak AD; Hicks-Berthet J; Kern JG; Abo K; Reid ME; Perdomo C; Wilson AA; Spira A; Beane J; Varelas X
Proc Natl Acad Sci U S A; 2021 May; 118(18):. PubMed ID: 33903236
[TBL] [Abstract][Full Text] [Related]
3. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
[TBL] [Abstract][Full Text] [Related]
4. The transcriptional regulators TAZ and YAP direct transforming growth factor β-induced tumorigenic phenotypes in breast cancer cells.
Hiemer SE; Szymaniak AD; Varelas X
J Biol Chem; 2014 May; 289(19):13461-74. PubMed ID: 24648515
[TBL] [Abstract][Full Text] [Related]
5. Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells.
Van Sciver N; Ohashi M; Pauly NP; Bristol JA; Nelson SE; Johannsen EC; Kenney SC
PLoS Pathog; 2021 Aug; 17(8):e1009783. PubMed ID: 34339458
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of YAP/TAZ-TEAD activity induces cytotrophoblast differentiation into syncytiotrophoblast in human trophoblast.
Mizutani T; Orisaka M; Miyazaki Y; Morichika R; Uesaka M; Miyamoto K; Yoshida Y
Mol Hum Reprod; 2022 Sep; 28(10):. PubMed ID: 35993908
[TBL] [Abstract][Full Text] [Related]
7. Yap/Taz inhibit goblet cell fate to maintain lung epithelial homeostasis.
Hicks-Berthet J; Ning B; Federico A; Tilston-Lunel A; Matschulat A; Ai X; Lenburg ME; Beane J; Monti S; Varelas X
Cell Rep; 2021 Jul; 36(2):109347. PubMed ID: 34260916
[TBL] [Abstract][Full Text] [Related]
8. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
[TBL] [Abstract][Full Text] [Related]
9. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
Mills KR; Misra J; Torabifard H
J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
[TBL] [Abstract][Full Text] [Related]
10. Mechanosignaling YAP/TAZ-TEAD Axis Regulates the Immunomodulatory Properties of Mesenchymal Stem Cells.
Yoshii H; Kajiya M; Yoshino M; Morimoto S; Horikoshi S; Tari M; Motoike S; Iwata T; Ouhara K; Ando T; Yoshimoto T; Shintani T; Mizuno N
Stem Cell Rev Rep; 2024 Jan; 20(1):347-361. PubMed ID: 37917410
[TBL] [Abstract][Full Text] [Related]
11. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth.
Zanconato F; Forcato M; Battilana G; Azzolin L; Quaranta E; Bodega B; Rosato A; Bicciato S; Cordenonsi M; Piccolo S
Nat Cell Biol; 2015 Sep; 17(9):1218-27. PubMed ID: 26258633
[TBL] [Abstract][Full Text] [Related]
13. YAP and TAZ are transcriptional co-activators of AP-1 proteins and STAT3 during breast cellular transformation.
He L; Pratt H; Gao M; Wei F; Weng Z; Struhl K
Elife; 2021 Aug; 10():. PubMed ID: 34463254
[TBL] [Abstract][Full Text] [Related]
14. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy.
Pobbati AV; Hong W
Theranostics; 2020; 10(8):3622-3635. PubMed ID: 32206112
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
[TBL] [Abstract][Full Text] [Related]
16. YAP/TAZ-TEAD is a novel transcriptional regulator of genes encoding steroidogenic enzymes in rat granulosa cells and KGN cells.
Mizutani T; Orisaka M; Kawabe S; Morichika R; Uesaka M; Yoshida Y
Mol Cell Endocrinol; 2023 Jan; 559():111808. PubMed ID: 36309205
[TBL] [Abstract][Full Text] [Related]
17. Role of the YAP/TAZ-TEAD Transcriptional Complex in the Metabolic Control of TRAIL Sensitivity by the Mevalonate Pathway in Cancer Cells.
El Yousfi Y; Mora-Molina R; López-Rivas A; Yerbes R
Cells; 2023 Sep; 12(19):. PubMed ID: 37830584
[TBL] [Abstract][Full Text] [Related]
18. A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23.
Saito Y; Yin D; Kubota N; Wang X; Filliol A; Remotti H; Nair A; Fazlollahi L; Hoshida Y; Tabas I; Wangensteen KJ; Schwabe RF
Gastroenterology; 2023 Jun; 164(7):1279-1292. PubMed ID: 36894036
[TBL] [Abstract][Full Text] [Related]
19. Detecting the Presence and Progression of Premalignant Lung Lesions via Airway Gene Expression.
Beane J; Mazzilli SA; Tassinari AM; Liu G; Zhang X; Liu H; Buncio AD; Dhillon SS; Platero SJ; Lenburg ME; Reid ME; Lam S; Spira AE
Clin Cancer Res; 2017 Sep; 23(17):5091-5100. PubMed ID: 28533227
[No Abstract] [Full Text] [Related]
20. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
[Next] [New Search]
